Volume 90, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Although ivermectin treatment can induce serious adverse events (SAEs) in individuals harboring high microfilaremia (mf), not all patients with high mf levels develop such reactions, suggesting that cofactors may be involved. A study was conducted in Cameroon to investigate the possible role of coinfection at the time of ivermectin treatment in the development of SAEs. Before their first ivermectin treatment, thick smears were obtained from 4,175 individuals to determine the burden of sp., , and . After treatment, 18 (4.3 per 1,000) patients developed a non-neurologic SAE. Logistic regression analysis, adjusting for age, sex, infection, and infection intensities, confirmed that mf was the main risk factor for SAEs. We found no evidence that coinfection with at the time of ivermectin treatment was associated with the occurrence of -related SAEs in this population.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Zouré HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.[Crossref]
    [Google Scholar]
  2. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J-P, 2003. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2 (Suppl 1): S4.[Crossref]
    [Google Scholar]
  3. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M, 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 1822.[Crossref]
    [Google Scholar]
  4. Kamgno J, Pion SD, Mackenzie CD, Thylefors B, Boussinesq M, 2009. Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events. Am J Trop Med Hyg 81: 10561061.[Crossref]
    [Google Scholar]
  5. Bourguinat C, Kamgno J, Boussinesq M, Mackenzie CD, Prichard RK, Geary TG, 2010. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event. Am J Trop Med Hyg 83: 2832.[Crossref]
    [Google Scholar]
  6. White V, Lewallen S, Beare N, Molyneux M, Taylor T, 2009. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS One 4: e4317.[Crossref]
    [Google Scholar]
  7. Kamgno J, Boussinesq M, Labrousse F, Nkegoum B, Thylefors BI, Mackenzie CD, 2008. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp. Am J Trop Med Hyg 78: 546551.
    [Google Scholar]
  8. Twum-Danso NAY, 2003. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2 (Suppl 1): S3.[Crossref]
    [Google Scholar]

Data & Media loading...

  • Received : 10 Apr 2013
  • Accepted : 23 Aug 2013
  • Published online : 05 Feb 2014

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error